Omeros Posts $57.4M Third-Quarter Loss
OMER has more than doubled off its 52-week low of $6.59.
Summary
Omeros reported a $57.4 million loss for the third quarter, or 79 cents a share, a sharp swing from the positive net income the company posted in Q2, when YARTEMLEA sales were surging. YARTEMLEA net revenue rose 26% in the quarter. The reversal matters because the bull case has rested on commercial traction for YARTEMLEA plus debt buybacks that were meant to curb dilution. A quarter this deep in the red raises the question of whether the Q2 profit was a one-off and how much cash the launch is actually consuming. The stock trades near $17.53 with a market cap around $1.2 billion, so a loss of this size is material relative to the equity base. Note the October 30 8-K granting CEO Gregory Demopulos up to 500,000 options at $17.88 that vest only on a much higher stock price — management is aligned to a recovery.
At the time of this announcement, OMER was trading at $17.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $6.59 to $21.24. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.